- TheStreet.com•1 hour ago
Drugmaker faced antitrust charges over 2013 Synacthen deal.
- MarketWatch•10 hours ago
Novartis CEO Joseph Jimenez spoke to WSJ's Deborah Ball about the impact that a Trump presidency could have on the pharmaceutical industry.
- Reuters•13 hours ago
Donald Trump's plans to cut U.S. corporate tax rates could trigger increased investment in the United States by Novartis, its chief executive told Reuters, despite the president-elect's recent harsh words on drug prices. "When we build a new manufacturing site we think about the tax rate, we think about the economy of the country, we think about jobs, so a booming U.S. economy would make the U.S. more attractive for investment," Joe Jimenez said on Wednesday. Trump unnerved drug company executives last week by saying the industry was "getting away with murder" on pricing and promising to introduce more competition to drive down costs.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||71.70 - 72.08|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||25.35|
|Dividend & Yield||2.72 (3.78%)|
|1y Target Est||N/A|